Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain

Clinical Journal of Pain

Volumn 27, Issue 8, 2011, Pages 664-667

  Kanbayashi, Yuko ^a,b,c   Hosokawa, Toyoshi ^a,d   Okamoto, Kousuke ^c   Fujimoto, Sawako ^a   Konishi, Hideyuki ^d   Otsuji, Eigo ^d   Yoshikawa, Toshikazu ^d   Takagi, Tatsuya ^c,d   Miki, Tsuneharu ^e   Taniwaki, Masafumi ^e  

^a Department of Pain Treatment and Palliative Care Unit ^*  (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c Nagoya City University   (Japan)

^d OSAKA UNIVERSITY   (Japan)

^e KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

cancer pain; morphine; opioid switching; oxycodone; transdermal fentanyl

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; BILIRUBIN; C REACTIVE PROTEIN; CREATININE; FENTANYL; HEMOGLOBIN; MORPHINE; OXYCODONE; PROTEIN;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BILE DUCT CARCINOMA; BLADDER CANCER; BREAST CANCER; CANCER PAIN; CANCER PATIENT; CHILD; COLON CANCER; CREATININE BLOOD LEVEL; DRUG MEGADOSE; DRUG RESPONSE; DRUG SUBSTITUTION; ESOPHAGUS CANCER; FEMALE; GENDER; HUMAN; KIDNEY CARCINOMA; KIDNEY PELVIS CARCINOMA; LIVER CANCER; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MYELOMA; OVARY CANCER; PANCREAS CANCER; PHARYNX CANCER; PREDICTOR VARIABLE; PRIORITY JOURNAL; SCHOOL CHILD; STOMACH CANCER; SUSTAINED RELEASE PREPARATION;

EID: 80052780470     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0b013e3182168fed     Document Type: Article

References (23)

1. Radbruch L, Sabatowski R, Loick G, et al. Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine. Palliat Med. 2000;14:111-119. (Pubitemid 30198020)
2. Ripamonti C, Fagnoni E, Campa T, et al. Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy. Support Care Cancer. 2006;14:400-407.
3. Morita T, Takigawa C, Onishi H, et al. Opioid rotation from morphine to fentanyl in delirious cancer patients: an open-label trial. J Pain Symptom Manage. 2005;30:96-103. (Pubitemid 41021684)
4. Allan L, Hays H, Jensen NH, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ. 2001;322: 1154-1158. (Pubitemid 32434223)
5. Menten J, Desmedt M, Lossignol D, et al. Longitudinal follow-up of TTS fentanyl use in patients with cancer-related pain: results of a compassionate use study with special focus on elderly patients. Curr Med Res Opin. 2002;18:488-498. (Pubitemid 36133051)
6. Benítez-Rosario MA, Feria M, Salinas-Martín A, et al. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain. Cancer. 2004;101:2866-2873. (Pubitemid 39603196)
7. Mercadante S, Ferrera P, Villari P, et al. Rapid switching between transdermal fentanyl and methadone in cancer patients. J Clin Oncol. 2005;23:5229-5234. (Pubitemid 46224034)
8. Clemens KE, Klaschik E. Clinical experience with transdermal and orally administered opioids in palliative care patients-a retrospective study. Jpn J Clin Oncol. 2007;37:302-309. (Pubitemid 47090683)
9. Donner B, Zenz M, Tryba M, et al. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain. 1996;64:527-534. (Pubitemid 26180159)
10. Heiskanen T, Mätzke S, Haakana S, et al. Transdermal fentanyl in cachectic cancer patients. Pain. 2009;144:218-222.
11. Van Nimmen NF, Poels KL, Menten JJ, et al. Fentanyl transdermal absorption linked to pharmacokinetic characteristics in patients undergoing palliative care. J Clin Pharmacol. 2010;50:667-678.
12. Solassol I, Caumette L, Bressolle F, et al. Inter-and intraindividual variability in transdermal fentanyl absorption in cancer pain patients. Oncol Rep. 2005;14:1029-1036.
13. Cicek M, Oursler MJ. Breast cancer bone metastasis and current small therapeutics. Cancer Metastasis Rev. 2006;25: 635-644. (Pubitemid 46071868)
14. Kanbayashi Y, Okamoto K, Ogaru T, et al. Statistical validation of the relationships of cancer pain relief with various factors using ordered logistic regression analysis. Clin J Pain. 2009;25:65-72.
15. Armstrong SC, Wynn GH, Sandson NB. Pharmacokinetic drug interactions of synthetic opiate analgesics. Psychosomatics. 2009;50:169-176.
16. Saari TI, Laine K, Neuvonen M, et al. Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl. Eur J Clin Pharmacol. 2008;64:25-30.
17. Kharasch ED, Whittington D, Hoffer C. Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. Anesthesiology. 2004;101:729-737. (Pubitemid 39121653)
18. Tegeder I, Lötsch J, Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet. 1999;37: 17-40. (Pubitemid 29366758)
19. Zhang W, Chang YZ, Kan QC, et al. CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients. Eur J Clin Pharmacol. 2010;66:61-66.
20. Otis J, Rothman M. A phase III study to assess the clinical utility of low-dose fentanyl transdermal system in patients with chronic nonmalignant pain. Curr Med Res Opin. 2006;22: 1493-1501. (Pubitemid 44297428)
21. Thompson JP, Bower S, Liddle AM, et al. Perioperative pharmacokinetics of transdermal fentanyl in elderly and young adult patients. Br J Anaesth. 1998;81:152-154.
22. Gupta SK, Hwang S, Southam M, et al. Effects of application site and subject demographics on the pharmacokinetics of fentanyl HCl patient-controlled transdermal system (PCTS). Clin Pharmacokinet. 2005;44:25-32. (Pubitemid 41626714)
23. Björkman S, Stanski DR, Verotta D, et al. Comparative tissue concentration profiles of fentanyl and alfentanil in humans predicted from tissue/blood partition data obtained in rats. Anesthesiology. 1990;72:865-873. (Pubitemid 20149223)